313 related articles for article (PubMed ID: 20079281)
1. [The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion].
Zhu QQ; Sun GY
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep; 32(9):674-8. PubMed ID: 20079281
[TBL] [Abstract][Full Text] [Related]
2. Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep.
Lee YC; Yasay JR; Johnson JE; Parker RE; Thompson PJ; Lane KB; Light RW
Respirology; 2002 Sep; 7(3):209-16. PubMed ID: 12153686
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Chung CL; Chen CH; Sheu JR; Chen YC; Chang SC
Chest; 2005 Aug; 128(2):690-7. PubMed ID: 16100155
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-β1 rise in pleural fluid after tunneled pleural catheter placement: pilot study.
Shojaee S; Voelkel N; Farkas L; de Wit M; Lee HJ
J Bronchology Interv Pulmonol; 2013 Oct; 20(4):304-8. PubMed ID: 24162112
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion.
Chung CL; Chen YC; Chang SC
Chest; 2003 Apr; 123(4):1188-95. PubMed ID: 12684310
[TBL] [Abstract][Full Text] [Related]
6. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta(2) (TGF beta(2)) produces effective pleurodesis in sheep with no systemic complications.
Lee YC; Lane KB; Parker RE; Ayo DS; Rogers JT; Diters RW; Thompson PJ; Light RW
Thorax; 2000 Dec; 55(12):1058-62. PubMed ID: 11083893
[TBL] [Abstract][Full Text] [Related]
8. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
Lombardi G; Nicoletto MO; Gusella M; Fiduccia P; Dalla Palma M; Zuin A; Fiore D; Donach M; Zagonel V
Cancer Chemother Pharmacol; 2012 Mar; 69(3):781-7. PubMed ID: 22037881
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions.
Sartori S; Tassinari D; Ceccotti P; Tombesi P; Nielsen I; Trevisani L; Abbasciano V
J Clin Oncol; 2004 Apr; 22(7):1228-33. PubMed ID: 15051770
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of metastatic pleural effusion with intrapleural administration of bleomycetin].
Akonov AL; Kondrat'ev VB
Vopr Onkol; 1999; 45(4):411-5. PubMed ID: 10532101
[TBL] [Abstract][Full Text] [Related]
11. A single intrapleural injection of transforming growth factor-beta(2) produces an excellent pleurodesis in rabbits.
Light RW; Cheng DS; Lee YC; Rogers J; Davidson J; Lane KB
Am J Respir Crit Care Med; 2000 Jul; 162(1):98-104. PubMed ID: 10903227
[TBL] [Abstract][Full Text] [Related]
12. Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
Hua CC; Chang LC; Chen YC; Chang SC
Chest; 1999 Nov; 116(5):1292-6. PubMed ID: 10559090
[TBL] [Abstract][Full Text] [Related]
13. Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
Hsu LH; Hsu PC; Liao TL; Feng AC; Chu NM; Kao SH
BMC Cancer; 2016 Jul; 16():463. PubMed ID: 27411914
[TBL] [Abstract][Full Text] [Related]
14. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
15. [Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells].
Min R; Li S; Wang H; Zhang J; Wang T; Yang Y
Zhonghua Nei Ke Za Zhi; 2000 Sep; 39(9):599-602. PubMed ID: 11798526
[TBL] [Abstract][Full Text] [Related]
16. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.
Stefani A; Natali P; Casali C; Morandi U
Eur J Cardiothorac Surg; 2006 Dec; 30(6):827-32. PubMed ID: 17113008
[TBL] [Abstract][Full Text] [Related]
17. [Impact of intrapleural hyperthermic perfusion on immunologic reaction state of cytokines TH1/TH2 of lung carcinoma patients with malignant pleural effusion].
Kang MQ; Cao YP; Deng F
Ai Zheng; 2008 Feb; 27(2):210-3. PubMed ID: 18279624
[TBL] [Abstract][Full Text] [Related]
18. [Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone].
Schmidt M; Schaarschmidt G; Chemaissani A
Pneumologie; 1997 Apr; 51(4):367-72. PubMed ID: 9221383
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
20. Repeated thoracenteses affect proinflammatory cytokines, vascular endothelial growth factor, and fibrinolytic activity in pleural transudates.
Chung CL; Yeh CY; Sheu JR; Chen YC; Chang SC
Am J Med Sci; 2007 Dec; 334(6):452-7. PubMed ID: 18091367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
